<DOC>
	<DOCNO>NCT01340820</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity AERAS-422 healthy , BCG-naïve adult .</brief_summary>
	<brief_title>Study AERAS 422 Healthy Adults</brief_title>
	<detailed_description>This Phase I , randomize , control , double-blind , dose-escalation study AERAS-422 . This study conduct 24 HIV-negative , healthy adult BCG-naïve negative prior exposure Mtb enrollment . The study conduct one clinical research site United States . AERAS-422 administer Study Day 0 single 0.1 mL intradermal ( ID ) injection contain either &gt; = 10^5 &lt; 10^6 CFU ( low-dose ) &gt; =10^6 CFU ( high-dose ) . BCG Tice® use active control AERAS-422 administer single 0.1 mL ID injection contain 1-8 x 10^5 CFU Study Day 0 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>≥18 year ≤45 year age randomization day Has general good health , confirm medical history physical examination Has screening body mass index ( BMI ) ≥19 &lt; 33 Females physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must use acceptable method avoid pregnancy 28 day prior randomization end study . Acceptable method avoid pregnancy Females physically capable pregnancy must : Negative urine pregnancy test within 21 day prior randomization AND within 24 hour prior Study Day 0 vaccination Ability complete protocol study visit reachable telephone Provided write informed consent prior screen evaluation Completed simultaneous enrollment Aeras Vaccine Registry protocol Acute illness randomization day Oral temperature &gt; =37.5 degrees C randomization day Abnormal laboratory value blood collect within 21 day prior randomization follow : Positive test hepatitis B core antibody hepatitis C antibody Positive test HIV Positive urine test opiate , cocaine , amphetamine Positive QuantiFERON®TB Gold test History treatment active latent tuberculosis infection Other evidence active latent tuberculosis , opinion investigator Tuberculin skin test ( TST ) within 90 day prior randomization History evidence allergic disease reaction opinion investigator likely exacerbate component AERAS422 BCG Tice History evidence autoimmune disease , immunosuppression , immunodeficiency , opinion investigator History evidence cheloid formation , axillary cervical lymphadenopathy , dermatologic anatomic finding , opinion investigator , may interfere assessment injection site reaction History evidence acute chronic disease condition , opinion investigator , may compromise safety subject interfere evaluation vaccine safety immunogenicity Medical , psychiatric , occupational , substance abuse problem , opinion investigator , make unlikely subject comply protocol Inability discontinue daily prescription medication ( except contraceptive ) study . Received immunosuppressive medication within 45 day prior randomization ( inhaled topical corticosteroid permit ) Received investigational drug vaccine product within 182 day prior randomization , plan participation investigational study study Received investigational Mtb vaccine time prior randomization Received vaccination immunotherapy BCG product time prior randomization Received immunoglobulin blood product within 45 day prior randomization Received inactivate influenza vaccine within 14 day prior randomization standard vaccine within 45 day prior randomization . Received systemic antibiotic within 14 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>